v3.26.1
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Cash flows from operating activities:        
Net income (loss) $ (1,121) $ (2,621) $ (2,949) $ 389
Adjustments to reconcile net loss to cash used in operating activities:        
Depreciation and amortization     89 132
Equity-based compensation     0 1
Amortization of right-of-use asset     57 104
Change in fair value of contingent consideration 52 159 240 295
Gain on early lease termination 0 0 0 (5,974)
Gain on settlement of accounts payables 0 0 0 (191)
Loss from sale or disposal of property and equipment (9) 60 28 86
Changes in operating assets and liabilities:        
Other receivable     50 1,434
Prepaid expenses and other current assets     380 169
Other noncurrent assets     0 (734)
Accounts payable     495 303
Accrued expenses     (419) 106
Net cash used in operating activities     (2,029) (3,880)
Cash flows from investing activities:        
Property and equipment     0 (320)
Proceeds from sale of fixed assets     0 40
Acquisition of GPCR Therapeutics USA Inc.     0 (2,090)
Net cash used in investing activities     0 (2,370)
Cash flows from financing activities:        
Proceeds from common stock offering     0 1,600
Net cash provided by provided by financing activities     0 1,600
Net decrease in cash and cash equivalents     (2,029) (4,650)
Cash and cash equivalents - beginning of period     3,746 12,508
Cash and cash equivalents - end of period $ 1,717 $ 7,858 $ 1,717 $ 7,858